

SUBJECT INDEX TO VOLUME 1

- A₃ Adenosine receptor antagonists.....417-424
 adenine derivatives as.....418
 dihydropyridines as.....421
 flavonoids as.....422
 imidazopurinones as.....417
 isoquinolines as.....420
 pyrazolo-triazolo-pyrimidines as.....420
 pyrrolopyrimidines as.....421
 quinazolines as.....420
 therapeutic applications for.....424
 triazoloquinazolines as.....418
 triazoloquinoxaline derivatives as.....420
 xanthines as.....417
- S-Adenosyl-L-homocysteine hydrolase.....307-314
 homoadenosine analogues for.....309
 5' modified adenosine analogues for.....308
 5' thioadenosine derivatives for.....313
- Acetylcholinesterase inhibitors.....255-263,256
 sites for.....268
 huprines as.....261
- 4-Aminopyridine thrombin inhibitors.....79-87
- AMPA receptor antagonists.....243-251
 2,3-benzodiazepines as.....244
 structure-activity relationship of.....249
- Amyloid aggregation inhibitors175-183
 for Alzheimer's disease175
 non-peptide amyloid aggregation inhibitors.....181
 peptide amyloid aggregation inhibitors.....179
- Angiotensin II.....210,211
- Antibody directed enzyme prodrug therapy.....399-406
 for cancer therapy.....399
- Antigen delivery systems429-436
 B-cell epitope in.....431
 lipid/polylysine core peptide system as.....433
 multiple antigenic peptide system as.....432
 self adjuvanting synthetic peptide-based immunogens.....435
 synthetic peptide vaccine in.....431
 T-cell epitope in.....431
- Antihypertensive drugs.....207-214
 angiotensin I receptor antagonist as.....209
 angiotensin II mimetics as.....208
 angiotensin-converting enzyme inhibitors as.....207
 renin inhibitors as.....207
- Anti-tumor necrosis factor design.....6,7
 current strategies in.....6,7
- Bioreductive drugs.....17-26
- Cantharidin.....47
 biological effects of.....47
 therapeutic uses of.....48
 structural-activity relationship of.....50
- Carbohydrates.....349-359
 enzymatic synthesis of.....352
 glycosyl transferase inhibitors of.....358
 solid phase synthesis of.....357
- Carboxylic esters.....101-108
 activation energy of.....103
 enzymatic hydrolysis of.....101
 stereoselectivity of.....103
 steric effects in.....105
 structure-metabolism relationship of.....104
- Carboxypeptidase A inhibitors.....155-160
 inhibitory stereochemistry of.....160
 irreversible inhibitors.....158
 substrate analog inhibitors156
- Catalytic antibodies.....125-131
 as enzyme mimics.....15
 drug inactivation by.....130
 for immunotherapy.....126
 prodrug activation by.....125,126
- DNA tetraplex-binding drugs.....31-40
 G-tetraplex-interactive ligands as.....33
 structure-selectivity of.....36
 telomerase inhibition by.....33
- Dopamine D₃ receptor.....89-97
 molecular cloning techniques for.....89
- Dopamine D₃ receptor ligands.....90-96
 benz[e]indole *cis*(±) as.....96
- FK506 binding proteins ligands.....377-389
 immunosuppressive peptidyl prolyl isomerases inhibitors of.....381
 in neuronal signaling.....384
 monofunctional FKBP.....381
- Flavoproteins.....293-304
 aerobic nitroreduction by.....293
 quinone reductase type 1.....297
 quinone reductase type 2.....298
- Fullerenes.....339-346
 as neuroprotective antioxidants.....344
 cell signaling by.....344
 DNA cleavage by.....339
 endohedral metallofullerenes.....346
 estradiol receptor binding by.....343
 HIV-1 protease inhibition by.....341
 photodynamic therapy by.....341
 role in apoptosis.....344
- Gene expression analysis.....197-204
 pharmaceutical target identification by.....197
- Gene-directed enzyme prodrug therapy301
- Glycosidase inhibitors.....145-152
 -galactosidase inhibitors as.....151
 -glycosidase inhibitors as.....145
 -mannosidase inhibitors as.....149
- Huprines.....163-172
 as acetylcholinesterase inhibitors.....163
 structure-activity relationship in.....165-171
 use in Alzheimer's disease.....163
- Inosine monophosphate dehydrogenase.....72
 drugs targeting on.....72
- Iron chelators233-240
- Iron-dependent oxidative stress.....235

- Leucine aminopeptidase.....133-142
 S1 binding pocket of.....141
- Leucine aminopeptidase inhibitors.....135
 analogues of amino acids as.....135-137
 analogues of peptides as.....138-141
- Lipopolysaccharides.....409-414
 antibacterial activity of.....409-414
 antiseptic activity of.....409-414
 structure of.....410
- Macromolecular-directed enzyme prodrug therapy.....303
- Modified tumor necrosis factors.....5-13
- Multiple sclerosis.....275
 autoantigens for.....275
 cyclic peptide mimetics for.....275
 cyclic non-peptide mimetics for.....275
 MBP epitope 74 -85 cyclic analogues for.....276
 Mannan conjugates for.....281
 non-peptide MBP epitope analogues for.....276
- N*-Oxides.....219-228
 aminoalkylaminoacridine *N*-oxide.....226
 aminoalkylaminoanthraquinone *N*-oxide.....225
 as hypoxia selective cytotoxins.....219
 benzo[1,2-*e*]1,2,4-triazine *N*¹,*N*⁴-dioxide.....220
 imidazoquinoxaline *N*-oxide.....222
 imidazopyridopyrazine *N*-oxide.....222
 quinoxaline *N,N*-dioxide.....224
- Nitric oxide.....58
 as biological mediator.....58
 gastric mucosal defence by.....58
- Non-nucleoside inosine monophosphate
 dehydrogenase inhibitors.....73-75
 high throughput screening for.....75
 monophosphate dehydrogenase-based approaches in.....73
- Nonsteroidal antiinflammatory drugs.....57
 gastrointestinal mucosal injury by.....57
- Opioid receptor like-1.....363-374
 non-peptidic ligands at.....363
- Oxidative stress activatable iron chelators.....238
- Peptide mimetics.....273-281
 for multiple sclerosis.....273
- Peptidomimetics.....8
 designing of.....8
- Peptidyl prolyl *cis/trans* isomerases379
- as signal transduction-targeted modulators.....386
- Polyamine toxins.....317-334
 solid phase synthesis of.....328
 structure-activity relationship investigations of.....321
- Protein phosphatase inhibitors.....47
 anhydride modifications in.....50
 multiple modification in.....52
 7-oxo-bridge modifications in.....50
 skeletal modifications in.....50
- Quantitative structure-activity relationship187 -192
 2 dimension QSAR.....187
 3 dimension QSAR.....190
 4 dimension QSAR.....192
 hologram QSAR.....189
 inverse QSAR.....189
- Quinoline antimalarials.....113-122
 antiplasmodial activity of.....120
 haemoglobin degradation by.....114
 inhibition of haemozoin formation by.....117
 interaction with haematin by.....115
 role of aminoalkyl side chain in.....120
- Serine/Threonine protein phosphatases.....43
 classification of.....43-52
 function of.....43
 inhibition of.....45
 structure of.....43
- TNF- inhibitor.....9
 designing of.....9
- Viral polymerase elongation subunits.....286
- Viral polymerase initiation subunits.....285
- Viral protein.....283-289
 photoaffinity modification of.....287